AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1103, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France. Source
No articles found.
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
Join the National Investor Network and get the latest information with your interests in mind.